NASDAQ:VIVO - Meridian Bioscience Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.4750 -0.33 (-2.23 %)
(As of 05/23/2018 08:25 AM ET)
Previous Close$14.80
Today's Range$14.45 - $14.85
52-Week Range$13.35 - $16.45
Volume106,490 shs
Average Volume254,408 shs
Market Capitalization$626.70 million
P/E Ratio21.60
Dividend Yield3.38%
Beta0.98

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Debt-to-Equity Ratio0.27
Current Ratio5.41
Quick Ratio3.71

Price-To-Earnings

Trailing P/E Ratio21.60
Forward P/E Ratio20.39
P/E GrowthN/A

Sales & Book Value

Annual Sales$200.77 million
Price / Sales3.05
Cash Flow$1.0288 per share
Price / Cash14.07
Book Value$4.12 per share
Price / Book3.51

Profitability

EPS (Most Recent Fiscal Year)$0.67
Net Income$21.55 million
Net Margins8.42%
Return on Equity16.66%
Return on Assets11.38%

Miscellaneous

Employees640
Outstanding Shares42,340,000

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience declared a quarterly dividend on Friday, April 27th. Investors of record on Monday, May 7th will be given a dividend of $0.125 per share on Thursday, May 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend is Friday, May 4th. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings data on Thursday, April, 26th. The company reported $0.21 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.21. The firm earned $56.45 million during the quarter, compared to analyst estimates of $55 million. Meridian Bioscience had a return on equity of 16.66% and a net margin of 8.42%. The company's quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.22 earnings per share. View Meridian Bioscience's Earnings History.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $0.69-0.72 for the period, compared to the Thomson Reuters consensus estimate of $0.71. The company issued revenue guidance of $209-214 million, compared to the consensus revenue estimate of $210.55 million.

What price target have analysts set for VIVO?

1 equities research analysts have issued 12 month price objectives for Meridian Bioscience's shares. Their predictions range from $16.00 to $16.00. On average, they expect Meridian Bioscience's share price to reach $16.00 in the next year. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:
  • Mr. John A. Kraeutler, Exec. Chairman (Age 70)
  • Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
  • Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
  • Mr. John P. Kenny, CEO & Director (Age 49)
  • Mr. Lawrence J. Baldini, Exec. VP & Pres of Global Operations (Age 59)

Has Meridian Bioscience been receiving favorable news coverage?

Media headlines about VIVO stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Meridian Bioscience earned a news sentiment score of 0.14 on Accern's scale. They also gave media headlines about the company an impact score of 45.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.72%), Dimensional Fund Advisors LP (4.30%), Systematic Financial Management LP (2.40%), Millennium Management LLC (1.98%), JPMorgan Chase & Co. (1.40%) and Schwab Charles Investment Management Inc. (1.34%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Millennium Management LLC, Wells Fargo & Company MN, Spark Investment Management LLC, JPMorgan Chase & Co., Mondrian Investment Partners LTD, Russell Investments Group Ltd. and Cornercap Investment Counsel Inc.. View Insider Buying and Selling for Meridian Bioscience.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, Systematic Financial Management LP, BlackRock Inc., Schwab Charles Investment Management Inc., GSA Capital Partners LLP, Susquehanna Fundamental Investments LLC, Hancock Holding Co. and Alambic Investment Management L.P.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $14.4750.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $626.70 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.67 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.


MarketBeat Community Rating for Meridian Bioscience (VIVO)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Meridian Bioscience (NASDAQ:VIVO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Meridian Bioscience in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 10.54%. The high price target for VIVO is $16.00 and the low price target for VIVO is $16.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.001.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.00$11.50
Price Target Upside: 10.54% upside0.00% downside0.00% downside23.08% downside

Meridian Bioscience (NASDAQ:VIVO) Consensus Price Target History

Price Target History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$14.00 ➝ $16.00LowView Rating Details
3/28/2017CL KingInitiated CoverageNeutral ➝ NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy ➝ HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Meridian Bioscience (NASDAQ:VIVO) Earnings History and Estimates Chart

Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Earnings Estimates

2018 EPS Consensus Estimate: $0.73
2019 EPS Consensus Estimate: $0.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.17$0.17$0.17
Q2 20181$0.22$0.22$0.22
Q3 20181$0.17$0.17$0.17
Q4 20182$0.16$0.17$0.17
Q1 20191$0.18$0.18$0.18
Q2 20191$0.19$0.19$0.19
Q3 20191$0.19$0.19$0.19
Q4 20191$0.19$0.19$0.19

Meridian Bioscience (NASDAQ VIVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018        
4/26/2018Q2 2018$0.21$0.21$55.00 million$56.45 millionViewN/AView Earnings Details
1/25/2018Q1 2018$0.14$0.15$49.00 million$52.30 millionViewN/AView Earnings Details
11/9/2017Q4 2017$0.15$0.15$48.28 million$49.70 millionViewN/AView Earnings Details
7/27/2017Q3 2017$0.16$0.16$49.13 million$50.14 millionViewN/AView Earnings Details
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.2420$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
11/11/2010Q4 2010$0.18$0.15ViewN/AView Earnings Details
7/20/2010Q3 2010$0.18$0.17ViewN/AView Earnings Details
4/20/2010Q2 2010$0.14$0.15ViewN/AView Earnings Details
1/21/2010Q1 2010$0.23$0.22ViewN/AView Earnings Details
11/12/2009Q4 2009$0.21$0.22ViewN/AView Earnings Details
7/16/2009Q3 2009$0.20$0.21ViewN/AView Earnings Details
4/16/2009Q2 2009$0.22$0.18ViewN/AView Earnings Details
1/22/2009Q1 2009$0.20$0.20ViewN/AView Earnings Details
11/12/2008Q4 2008$0.18$0.19ViewN/AView Earnings Details
7/17/2008Q3 2008$0.19$0.19ViewN/AView Earnings Details
4/17/2008Q2 2008$0.19$0.18ViewN/AView Earnings Details
1/22/2008Q1 2008$0.17$0.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Meridian Bioscience (NASDAQ:VIVO) Dividend Information

Meridian Bioscience pays an annual dividend of $0.50 per share, with a dividend yield of 3.45%. VIVO's most recent quarterly dividend payment was Thursday, May 17. Meridian Bioscience pays out 74.63% of its earnings out as a dividend.
Most Recent Dividend:5/17/2018
Annual Dividend:$0.50
Dividend Yield:3.45%
Payout Ratio(s):74.63% (Trailing 12 Months of Earnings)
70.42% (Based on This Year's Estimates)
64.94% (Based on Next Year's Estimates)
48.60% (Based on Cash Flow)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2018quarterly$0.12503.41%5/4/20185/7/20185/17/2018
1/24/2018Quarterly$0.12503.52%2/2/20182/5/20182/15/2018
11/8/2017Quarterly$0.12503.44%11/17/201711/20/201711/30/2017
7/27/2017Quarterly$0.12503.55%8/3/20178/7/20178/17/2017
4/27/2017quarterly$0.12503.33%5/4/20175/8/20175/18/2017
1/25/2017quarterly$0.12503.91%2/2/20172/6/20172/16/2017
11/10/2016Quarterly$0.204.6%11/17/201611/21/201612/1/2016
7/28/2016quarterly$0.204.13%8/4/20168/8/20168/18/2016
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013
12/4/2012quarterly$0.1912/14/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Meridian Bioscience (NASDAQ VIVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 86.97%
Insider Trading History for Meridian Bioscience (NASDAQ:VIVO)
Insider Trading History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2018John McilwraithDirectorBuy1,000$14.03$14,030.004,000View SEC Filing  
2/7/2018John Mccune Jr. RiceDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/24/2017John A KraeutlerChairmanBuy7,000$13.67$95,690.00345,230View SEC Filing  
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00167,071View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00106,934View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.9052,926View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.407,000View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.0048,719View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00316,683View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.0095,501View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.003,000View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.007,700View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.0054,459View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.7446,219View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.3450,500View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48106,702View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.0040,755View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.7675,500View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50270,718View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Meridian Bioscience (NASDAQ VIVO) News Headlines

Source:
DateHeadline
Meridian Bioscience (VIVO) Presents At 2018 UBS Global Healthcare Conference - SlideshowMeridian Bioscience (VIVO) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 22 at 5:18 PM
Meridian Bioscience (VIVO) versus Vermillion (VRML) Head-To-Head SurveyMeridian Bioscience (VIVO) versus Vermillion (VRML) Head-To-Head Survey
www.americanbankingnews.com - May 20 at 5:25 AM
Critical Survey: Meridian Bioscience (VIVO) & Immunomedics (IMMU)Critical Survey: Meridian Bioscience (VIVO) & Immunomedics (IMMU)
www.americanbankingnews.com - May 12 at 3:21 AM
$51.96 Million in Sales Expected for Meridian Bioscience (VIVO) This Quarter$51.96 Million in Sales Expected for Meridian Bioscience (VIVO) This Quarter
www.americanbankingnews.com - May 10 at 5:13 AM
Meridian Bioscience (VIVO) Expected to Post Earnings of $0.17 Per ShareMeridian Bioscience (VIVO) Expected to Post Earnings of $0.17 Per Share
www.americanbankingnews.com - May 8 at 1:14 AM
Meridian Bioscience (VIVO) Upgraded at Zacks Investment ResearchMeridian Bioscience (VIVO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 1 at 3:10 PM
Is Buying Meridian Bioscience Inc (NASDAQ:VIVO) For Its Upcoming $0.13 Dividend A Good Choice?Is Buying Meridian Bioscience Inc (NASDAQ:VIVO) For Its Upcoming $0.13 Dividend A Good Choice?
finance.yahoo.com - April 30 at 5:26 PM
Comparing New England Nuclear (LNTH) and Meridian Bioscience (VIVO)Comparing New England Nuclear (LNTH) and Meridian Bioscience (VIVO)
www.americanbankingnews.com - April 30 at 3:20 PM
Q4 2018 EPS Estimates for Meridian Bioscience Increased by Piper Jaffray (VIVO)Q4 2018 EPS Estimates for Meridian Bioscience Increased by Piper Jaffray (VIVO)
www.americanbankingnews.com - April 30 at 4:01 AM
FY2018 EPS Estimates for Meridian Bioscience (VIVO) Lifted by AnalystFY2018 EPS Estimates for Meridian Bioscience (VIVO) Lifted by Analyst
www.americanbankingnews.com - April 30 at 3:26 AM
Meridian Bioscience (VIVO) to Issue Quarterly Dividend of $0.13Meridian Bioscience (VIVO) to Issue Quarterly Dividend of $0.13
www.americanbankingnews.com - April 27 at 6:00 PM
Meridian Bioscience: Fiscal 2Q Earnings SnapshotMeridian Bioscience: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - April 26 at 5:28 PM
Meridian Bioscience (VIVO) Posts Quarterly  Earnings Results, Meets EstimatesMeridian Bioscience (VIVO) Posts Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - April 26 at 2:18 PM
Meridian Bioscience (VIVO) Issues FY18 Earnings GuidanceMeridian Bioscience (VIVO) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 9:26 AM
Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 GuidanceMeridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance
finance.yahoo.com - April 26 at 8:02 AM
Comparing Quotient (QTNT) and Meridian Bioscience (VIVO)Comparing Quotient (QTNT) and Meridian Bioscience (VIVO)
www.americanbankingnews.com - April 25 at 11:16 PM
$54.39 Million in Sales Expected for Meridian Bioscience, Inc. (VIVO) This Quarter$54.39 Million in Sales Expected for Meridian Bioscience, Inc. (VIVO) This Quarter
www.americanbankingnews.com - April 22 at 1:02 AM
Zacks: Brokerages Expect Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPSZacks: Brokerages Expect Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS
www.americanbankingnews.com - April 20 at 11:14 PM
Meridian Bioscience (VIVO) to Release Quarterly Earnings on ThursdayMeridian Bioscience (VIVO) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 3:16 AM
Meridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment ResearchMeridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM
Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $54.00 MillionZacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $54.00 Million
www.americanbankingnews.com - April 6 at 5:16 AM
Meridian Bioscience (VIVO) Cut to "Sell" at Zacks Investment ResearchMeridian Bioscience (VIVO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:00 PM
 Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.20 Per Share Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.20 Per Share
www.americanbankingnews.com - April 4 at 1:22 AM
Zacks Investment Research Downgrades Meridian Bioscience (VIVO) to HoldZacks Investment Research Downgrades Meridian Bioscience (VIVO) to Hold
www.americanbankingnews.com - March 29 at 3:00 PM
Meridian Bioscience (VIVO) Realigns Organizational StructureMeridian Bioscience (VIVO) Realigns Organizational Structure
www.streetinsider.com - March 21 at 5:53 PM
Meridian Bioscience (VIVO) Raised to Buy at Zacks Investment ResearchMeridian Bioscience (VIVO) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 21 at 2:13 PM
Meridian Bioscience Realigns Business Structure - Quick FactsMeridian Bioscience Realigns Business Structure - Quick Facts
www.rttnews.com - March 21 at 8:16 AM
Meridian Bioscience Realigns Organizational StructureMeridian Bioscience Realigns Organizational Structure
finance.yahoo.com - March 21 at 8:16 AM
 Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million
www.americanbankingnews.com - March 19 at 2:26 AM
Meridian Bioscience, Inc. (VIVO) Expected to Post Earnings of $0.20 Per ShareMeridian Bioscience, Inc. (VIVO) Expected to Post Earnings of $0.20 Per Share
www.americanbankingnews.com - March 17 at 11:14 PM
Meridian Bioscience (VIVO) Raised to "Hold" at BidaskClubMeridian Bioscience (VIVO) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 10 at 10:28 PM
Connors Investor Services Inc. Decreases Stake in Meridian Bioscience, Inc. (VIVO)Connors Investor Services Inc. Decreases Stake in Meridian Bioscience, Inc. (VIVO)
www.americanbankingnews.com - March 5 at 1:54 PM
Meridian Bioscience, Inc. (VIVO) Position Lifted by Martingale Asset Management L PMeridian Bioscience, Inc. (VIVO) Position Lifted by Martingale Asset Management L P
www.americanbankingnews.com - March 3 at 11:50 AM
Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 MillionZacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million
www.americanbankingnews.com - March 2 at 2:28 AM
Spark Investment Management LLC Has $2.89 Million Stake in Meridian Bioscience, Inc. (VIVO)Spark Investment Management LLC Has $2.89 Million Stake in Meridian Bioscience, Inc. (VIVO)
www.americanbankingnews.com - February 28 at 5:44 PM
American Century Companies Inc. Purchases Shares of 137,306 Meridian Bioscience, Inc. (VIVO)American Century Companies Inc. Purchases Shares of 137,306 Meridian Bioscience, Inc. (VIVO)
www.americanbankingnews.com - February 27 at 4:06 AM
Insider Buying: Meridian Bioscience, Inc. (VIVO) Director Buys 1,000 Shares of StockInsider Buying: Meridian Bioscience, Inc. (VIVO) Director Buys 1,000 Shares of Stock
www.americanbankingnews.com - February 26 at 12:16 PM
Contrasting Meridian Bioscience (VIVO) and Lombard Medical (EVARF)Contrasting Meridian Bioscience (VIVO) and Lombard Medical (EVARF)
www.americanbankingnews.com - February 18 at 7:02 PM
Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 MillionMeridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 Million
www.americanbankingnews.com - February 14 at 12:46 PM
Lawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders FoundationLawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders Foundation
finance.yahoo.com - February 12 at 3:33 PM
 Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS
www.americanbankingnews.com - February 12 at 5:12 AM
Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 SharesMeridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares
www.americanbankingnews.com - February 8 at 4:20 AM
Active-Investors: Free Post Earnings Research Report: Meridians Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%Active-Investors: Free Post Earnings Research Report: Meridian's Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%
www.finanznachrichten.de - February 5 at 8:00 AM
Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%
finance.yahoo.com - February 5 at 8:00 AM
Meridian Bioscience (VIVO) Downgraded to Sell at BidaskClubMeridian Bioscience (VIVO) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - February 3 at 1:38 PM
William Blair Comments on Meridian Bioscience, Inc.s FY2019 Earnings (VIVO)William Blair Comments on Meridian Bioscience, Inc.'s FY2019 Earnings (VIVO)
www.americanbankingnews.com - January 29 at 7:46 AM
Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13
www.americanbankingnews.com - January 28 at 7:31 AM
 Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million
www.americanbankingnews.com - January 28 at 5:48 AM
Meridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord GenuityMeridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - January 26 at 3:18 PM
Head-To-Head Analysis: Zimmer Biomet (ZBH) & Meridian Bioscience (VIVO)Head-To-Head Analysis: Zimmer Biomet (ZBH) & Meridian Bioscience (VIVO)
www.americanbankingnews.com - January 26 at 1:30 PM

SEC Filings

Meridian Bioscience (NASDAQ:VIVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Meridian Bioscience (NASDAQ:VIVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Meridian Bioscience (NASDAQ VIVO) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.